Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials-Reference-Cited by-同舟云学术

Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials

Published:2017 Issue:3 Volume:2 Page:e000236
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Ramos-Esquivel Allan,van der Laat Alicia,Rojas-Vigott Raquel,Juárez Melissa,Corrales-Rodríguez Luis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Cancer statistics, 2016;Siegel;CA: A Cancer Journal for Clinicians,2016

2. World Health Organization.International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in2012. http://globocan.iarc.fr/Default.aspx (accessed May 30, 2017).

3. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

4. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Novello;Ann Oncol,2016

5. Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials;He;Onco Targets Ther,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The genomic landscape of the immune system in lung cancer: present insights and continuing investigations;Frontiers in Genetics;2024-06-25

2. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-19

3. An Overview of Lung Cancer;International Journal of Innovative Science and Research Technology (IJISRT);2024-05-07

4. The interactions of docetaxel with tumor microenvironment;International Immunopharmacology;2023-06

5. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy;Frontiers in Immunology;2023-01-26